FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and is intended for the treatment of hepatitis C virus. Pan-genotypic HCV inhibitors are used, in particular methyl {(2S,3R)-1-[(2S)-2-{5-[(2R,5R)-1-{3,5-difluoro-4-[4-(4-fluorophenyl)piperidin-1-yl]phenyl}-5-(6-fluoro-2-{(2S)-1-N-(methoxycarbonyl)-O-methyl-L-threonyl]pyrrolidin-2-yl}-1H-benzimidazol-5-yl) pyrrolidin-2-yl)-6-fluoro-1H-benzimidazol-2-yl}pyrrolidin-1-yl]-3-methoxy-1-oxobutan-2-yl}carbamate together with an HCV protease inhibitor or HCV polymerase inhibitor. Patient is not genotyped for this treatment, the treatment lasts at least 24 weeks and does not include the administration of interferon.
EFFECT: group of inventions improves effectiveness of treatment.
13 cl, 3 tbl, 2 ex
